Patents by Inventor Shuzo Yamashita
Shuzo Yamashita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220033974Abstract: To provide a magnesium alloy with improved corrosion resistance by surface modification, and a production method thereof. (1) The surface-modified magnesium alloy comprising: a magnesium alloy having an arbitrary shape; a magnesium fluoride layer formed by fluorination of the surface of the magnesium alloy; and a diamond-like carbon layer formed on the magnesium fluoride layer. (2) The method comprising: subjecting a surface of a magnesium alloy having an arbitrary shape to fluorination treatment to form a magnesium fluoride layer on the surface of the magnesium alloy, and then subjecting the magnesium alloy with the magnesium fluoride layer to be placed in a high-frequency plasma CVD device such that a source gas containing carbon is introduced to form a diamond-like carbon layer on the magnesium fluoride layer.Type: ApplicationFiled: September 27, 2021Publication date: February 3, 2022Inventors: Shuzo YAMASHITA, Makoto SASAKI, Akira WADA
-
Publication number: 20220008625Abstract: A bioabsorbable implant for non-luminal region comprising: a core structure including a magnesium alloy having a predetermined shape; a first corrosion-resistant layer containing a magnesium fluoride layer as a main component formed on the core structure via fluorination of a surface of the magnesium alloy; and a second corrosion-resistant layer containing a parylene formed on the magnesium fluoride layer.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Inventors: Shuzo YAMASHITA, Makoto SASAKI, Akira WADA
-
Patent number: 11207448Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.Type: GrantFiled: May 24, 2018Date of Patent: December 28, 2021Assignees: JAPAN MEDICAL DEVICE TECHNOLOGY CO., LTD., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Makoto Sasaki, Takuro Niidome, Zhen Yu Jin, Shuzo Yamashita
-
Publication number: 20210353836Abstract: Provided are a magnesium alloy stent with improved corrosion resistance, and a method for producing same. The bioabsorbable stent including a core structure of a magnesium alloy, the stent is composed of: a first anticorrosive layer containing magnesium fluoride as a main component formed on the core structure, and a second anticorrosive layer coated with a diamond-like carbon on the first anticorrosive layer.Type: ApplicationFiled: July 28, 2021Publication date: November 18, 2021Inventors: Shuzo YAMASHITA, Makoto SASAKI, Akira WADA
-
Publication number: 20210001013Abstract: Provided is a biodegradable stent comprising a magnesium alloy free of a rare earth element and aluminum. The stent comprises: a core structure comprising a magnesium alloy containing 90 wt % or more of magnesium as a main component, and zinc, zirconium, and manganese as accessary components, the magnesium alloy being free of a rare earth element and aluminum; a first corrosion resistant layer formed on the core structure and containing magnesium fluoride as a main component; and a second corrosion resistant layer formed on the first corrosion resistant layer and comprising a parylene. A method for producing such a bioabsorbable stent is also provided.Type: ApplicationFiled: September 17, 2020Publication date: January 7, 2021Inventors: Makoto SASAKI, Yuki KOGA, Yuki OKAZAWA, Hironori UEDA, Masashi INOUE, Shuzo YAMASHITA
-
Publication number: 20180264180Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicants: Japan Medical Device Technology Co., Ltd., National University Corporation Kumamoto UniversityInventors: Makoto SASAKI, Takuro NIIDOME, Zhen Yu JIN, Shuzo YAMASHITA
-
Patent number: 9040111Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.Type: GrantFiled: December 28, 2012Date of Patent: May 26, 2015Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8968392Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: GrantFiled: July 30, 2012Date of Patent: March 3, 2015Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo IwataInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8641756Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: June 8, 2012Date of Patent: February 4, 2014Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata Institute for Frontier Medical Sciences, Kyoto UniversityInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8435287Abstract: A stent includes a tubular stent body 11, a diamond-like carbon film 12 formed on the surface of the stent body 11 and having an activated surface, and a polymer layer 13 immobilized on the surface of the diamond-like carbon film. The polymer layer 13 contains a drug 14 having an effect to prevent restenosis, and the drug 14 is gradually released from the polymer layer 13.Type: GrantFiled: January 15, 2007Date of Patent: May 7, 2013Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., LtdInventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Ikuo Komura, Koji Mori
-
Patent number: 8409272Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: September 3, 2008Date of Patent: April 2, 2013Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20130018455Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: ApplicationFiled: July 30, 2012Publication date: January 17, 2013Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20120310329Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: June 8, 2012Publication date: December 6, 2012Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo OMURA, Zhen Yu JIN, Shuzo YAMASHITA, Hiroo IWATA, Akira MOCHIZUKI
-
Patent number: 7931934Abstract: A medical device includes a medial device body, and a diamond-like thin film covering the medical device body and containing silicon. The diamond-like thin film has a concentration of silicon which is lower in a surface thereof than in an interface thereof with the medical device body mentioned above, and continuously varies.Type: GrantFiled: January 15, 2007Date of Patent: April 26, 2011Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., Ltd.Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Koji Mori, Ikuo Komura
-
Publication number: 20110060403Abstract: A stent includes a tubular stent body 11, a diamond-like carbon film 12 formed on the surface of the stent body 11 and having an activated surface, and a polymer layer 13 immobilized on the surface of the diamond-like carbon film. The polymer layer 13 contains a drug 14 having an effect to prevent restenosis, and the drug 14 is gradually released from the polymer layer 13.Type: ApplicationFiled: January 15, 2007Publication date: March 10, 2011Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Ikuo Komura, Koji Mori
-
Publication number: 20100249914Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: June 2, 2010Publication date: September 30, 2010Applicants: HIROO IWATAInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20100198344Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: September 3, 2008Publication date: August 5, 2010Applicants: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20090209942Abstract: A medical device includes a medial device body, and a diamond-like thin film covering the medical device body and containing silicon. The diamond-like thin film has a concentration of silicon which is lower in a surface thereof than in an interface thereof with the medical device body mentioned above, and continuously varies.Type: ApplicationFiled: January 15, 2007Publication date: August 20, 2009Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Koji Mori, Ikuo Komura
-
Publication number: 20090131271Abstract: In a method for delivering a nucleic acid of the invention, a nucleic acid is introduced into a cell by pressing the nucleic acid supported on a surface of a solid substrate against the cell. According to the method, the nucleic acid can be delivered into the cell simply at a low cost without placing a heavy burden on the cell at a high nucleic acid delivery efficiency. By allowing the surface of the solid substrate to support the nucleic acid in the form of a complex with a polyamine or a cationic lipid and pressing it against the cell, the introduction efficiency into the cell can be further improved. In the invention, by using a nucleic acid useful for gene therapy as the nucleic acid, a high-efficiency device for gene therapy can be obtained.Type: ApplicationFiled: May 16, 2006Publication date: May 21, 2009Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, JAPAN STENT TECHNOLOGY CO, LTD.Inventors: Takuro Niidome, Fumio Wada, Yoshiki Katayama, Kosuke Yakumaru, Takahito Kawano, Shuzo Yamashita
-
Publication number: 20090005862Abstract: A stent includes a tubular stent body 11, a diamond-like carbon film 12 formed on the surface of the stent body 11 and having an activated surface, and a polymer layer 13 immobilized on the surface of the diamond-like carbon film. The polymer layer 13 contains a drug 14 having an effect to prevent restenosis, and the drug 14 is gradually released from the polymer layer 13.Type: ApplicationFiled: January 15, 2007Publication date: January 1, 2009Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Ikuo Komura, Koji Mori